A director of oncology translational medicine at a top pharma company is interested in NGS for analysis of both tumor tissue and ctDNA. They think the non-Illumina vendors are still very early in the space, but nonetheless is considering how and when they may begin to incorporate these newer technologies. They currently utilize Illumina and Oxford Nanopore, are actively considering PacBio, Ultima, and Element, and they are familiar with Thermo Fisher, MGI, and Singular. Their greatest pain points are sample collection, sample prep, and library prep. When purchasing instruments, they prioritize company track record, accuracy, and throughput. They think it will be difficult to switch away from Illumina because of Illumina’s entrenchment and technical strengths.
PDF deck with summarized feedback from stakeholders
Individual PDFs of call transcripts with stakeholders
This package includes both the PDF deck and transcripts, providing a comprehensive understanding of stakeholders' views. You will receive a summarized report in the form of a PDF deck, as well as the full transcript of the discussions.
Individual call transcript of a single stakeholder discussing their views. This option is ideal for those who are interested in a specific stakeholder's perspective and insights on the topic.